Clade Therapeutics has raised US$87m in a Series A led by Syncona Ltd with participation from LifeSci Venture Partners, Emerson Collective and Bristol Myers Squibb (BMS).
Stem cell therapy developers are lacking production scale-up technologies, says the chair of an upcoming conference bringing industry and academia together to address the problem.
Lonza has published a guide to clinical-grade induced pluripotent stem cell (IPSC) manufacture, addressing concerns around the derivation of cellular materials.
Mass produced regenerative therapies are a step closer say UK researchers who have developed a polymer substrate they claim can be used to set up “stem cell factories.”
California-based Allele has bought a facility to manufacture human induced pluripotent stem cells (hiPSCs) using its “footprint-free” synthetic mRNA technology.
Novartis says stem cell-based therapies will form an important part of its pipeline after reports in the Israeli media the firm pulled out of a deal to buy Gamida Cell.
Scientists at the University of Nottingham have created a new combination of hydrogels that allows dense tissue structures to be produced from human pluripotent stem cells (HPSC) in a single step process never achieved before.
